Latest Protox Therapeutics (PTXRF) Headlines
Post# of 1
Posted On: 03/11/2014 2:54:33 AM
Latest Protox Therapeutics (PTXRF) Headlines
Benign Prostatic Hyperplasia - Pipeline Review, H2 2013
M2 - Mon Sep 02, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r9fndv/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2013" report to their offering. 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. Scope - A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia. - A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Eli Lilly and Company Light Sciences Oncology, Inc. Ipsen S.A. Aphios Corporation Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Dong-A Pharmaceutical Co., Ltd. Addex Pharmaceuticals AEterna Zentaris Inc. IntelGenx Technologies Corp. Kaken Pharmaceutical Co.,Ltd. Karo Bio Nymox Pharmaceutical Corporation Quest PharmaTech Inc. Plethora Solutions Holdings plc Protox Therapeutics Inc. AndroScience Corporation NovaLead Pharma Pvt. Ltd. EndoCeutics, Inc. AmVac AG KAEL-GemVax Ausio Pharmaceuticals, LLC Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/r9..._prostatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Board of Directors of Carmanah Technologies Corporation Announces the Appointment of John Simmons as President and CEO
Business Wire - Thu Jun 27, 9:07AM CDT
The Board of Directors of Carmanah Technologies Corporation (TSX: CMH) announces the appointment of John Simmons as President and CEO.
Benign Prostatic Hyperplasia - Pipeline Review, H2 2013
M2 - Mon Sep 02, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r9fndv/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2013" report to their offering. 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. Scope - A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia. - A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Eli Lilly and Company Light Sciences Oncology, Inc. Ipsen S.A. Aphios Corporation Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Dong-A Pharmaceutical Co., Ltd. Addex Pharmaceuticals AEterna Zentaris Inc. IntelGenx Technologies Corp. Kaken Pharmaceutical Co.,Ltd. Karo Bio Nymox Pharmaceutical Corporation Quest PharmaTech Inc. Plethora Solutions Holdings plc Protox Therapeutics Inc. AndroScience Corporation NovaLead Pharma Pvt. Ltd. EndoCeutics, Inc. AmVac AG KAEL-GemVax Ausio Pharmaceuticals, LLC Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/r9..._prostatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Board of Directors of Carmanah Technologies Corporation Announces the Appointment of John Simmons as President and CEO
Business Wire - Thu Jun 27, 9:07AM CDT
The Board of Directors of Carmanah Technologies Corporation (TSX: CMH) announces the appointment of John Simmons as President and CEO.
(0)
(0)Protox Therapeutics (PTXRF) Stock Research Links
Scroll down for more posts ▼